You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Hims & Hers may not be hurt by GLP-1 news the way investors think.
Shares of Hims & Hers (HIMS -7.01%) fell as much as 15% on Thursday after news that Eli Lilly's (LLY 1.80%) GLP-1 drug was taken off the shortage list by the FDA. This could impact Hims & Hers' GLP-1 strategy, but it may not have the impact you think. In this video, Travis Hoium covers the day's news and why this isn't a big deal for investors.
*Stock prices used were end-of-day prices of Oct. 3, 2024. The video was published on Oct. 3, 2024.
Travis Hoium has positions in Hims & Hers Health. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
